Intercellular communication between cancer and surrounding stromal cells contributes to the creation of a local microenvironment that promotes tumor survival and growth (Figure 1 ). EVs have come into the limelight as pivotal mediators of this 'corrupting' process. Different types of EV can be distinguished based on their subcellular origin. Exosomes are EVs originating in intraluminal vesicles that are released from multivesicular bodies on plasma membrane fusion, while microvesicles and large oncosomes are other classes of EV produced at the plasma membrane by budding or blebbing, respectively. Here they are referred to collectively as EVs, as there is neither a reliable marker nor a method available to distinguish and separate them from each other in conditioned tissue-culture medium. EVs are lipid bilayer transport vesicles containing diverse molecular cargoes (lipids, proteins, DNA, mRNA, metabolites, and a huge number of various noncoding RNAs such as lncRNA, tRNA, rRNA, snoRNA, and scaRNA) that depend on the physiology of the cell of origin. As tumors progress, the cargo released on/in EVs also dynamically changes. This short overview outlines the role of tumor-secreted EVs in governing immune evasion, vascularization, and stromal activation and how this shapes cancer progression.
EVs: Recalibrating Local Immune Evasion
Cargo released by EVs can suppress the function of local immune populations. For instance, it was reported that head and neck squamous cell carcinoma (HNSCC) cell line PCI-13-derived EVs change the gene expression profile of various subsets of T cells, especially activated regulatory T cells (Tregs), by upregulating critical immunoinhibitory proteins such as TGFb, IL-10, and COX-2, as well as CD39, or CD73 and adenosine production [1] . Which EV cargo causes this upregulation remains to be determined. Cancer EVs can also attenuate the cytotoxic function of CD8 + T cells, causing tumor immune (Figure 2 ). modulate neoangiogenesis, although how they participate in tip cell versus stalk cell determination remains elusive, as opposing mechanisms that promote or inhibit vascular branching have been proposed [3, 4] . High-level expression of Wnt5A in melanoma cells can also induce the release of EVs containing immune regula-tory and proangiogenic proteins, including IL-6, VEGF, and MMP2 [5] .
Beyond vas-cular signaling, cancer EVs also modify endothelial tube formation under hypoxic conditions through miRNA cargo [6] . EVs are also involved in the modulation of lymphangiogenesis, as MDCK cells overexpressing podoplanin (PDPN) undergo epithelial-mesenchymal transition (EMT) and stimulate the release of positive EVs that significantly stimulated both the length of tubes and the number of closed capillary-like structures, thus promoting lymphatic vessel formation [7] .
EVs: Modifying Cancer
Cell-Fibroblast Interactions Cancerassociated fibroblasts (CAFs) are phenotypically different fibroblasts, characterized by increased proliferation rate, migratory properties, and heightened deposition of extracellular matrix (ECM), that are abundant in the stroma of many solid tumors. CAFs can derive from normal resident fibroblasts, transdifferentiation of mesenchymal stem cells (MSCs), or EMT of cancer cells, processes regulated by TGFb, PDGF, FGF2, and other factors and molecules including miRNAs.
Experimental evidence shows that cancer-derived EVs can induce the CAF phenotype in various cancer contexts. For example: breast cancer cells EV carrying TGFb can differentiate adipose tissuederived MSCs into /-smooth muscle actin-positive CAFs through the TGFb-Smad pathway [8] ; prostate cancer EVs can induce proangiogenic and invasive CAFs from bone marrow MSCs [9] ; and bladder cancer EVs can induce CAFs by promoting EMT of urothelial cells [10] . It has also been shown that EVs derived from blood cancers, such as chronic lymphocytic leukemia, can convert endothelial cells and bone marrow-derived MSCs into CAFs [11] .
Stromal cells also secrete EVs that reprogram the environment and cancer cells. In breast cancer, a complex bidirectional interaction of cancer and stromal EVs was observed; fibroblast-derived EVs are taken up by cancer cells, loaded with Wnt11 protein, and then released into the tumor where Wnt11 activates autocrine Wnt planar cell-polarity signaling at the leading edge of cancer cells, promoting cell migration [12] . Stromal EVs can also have profound effects on protection from drug treatment and MSC-derived EVs were shown to induce development of drug resistance in gastric cancer cells in vivo and ex vivo by activating the CaMK-Raf-MEK-ERK pathway [13] . Finally, metabolomic analyses of CAF-derived EVs revealed that they carry metabolites such as amino acids, lipids, and tricarboxylic acid (TCA) cycle intermedi-ates that can strikingly reprogram the 
EVs: Reshaping the Tumor and Lymphatic Vasculature
The content of tumor cell-derived EVs was shown to include von Willebrand factor and VEGF, mutated EGFR, and other factors that promote the proliferation, migration, and maturation of vascular endothelial cells and, therefore, can contribute to restructuring the tumor vasculature. By apparent contrast, EVs can also release vascular inhibitors such as Deltalike 4 (Dll4) (a Notch signaling inhibitory ligand). Together with endothelially derived EVs that also transport Dll4, they metabolism of cancer cells; for instance, by affecting the generation of energy in the acceptor cancer cells [14] .
Concluding Remarks
These few examples provide an outline of the much bigger spectrum of EVs as modulators of the tumor environment. As our knowledge of the biology of EVs increases, so do opportunities to use this knowledge to design better diagnostic tools and targeted therapies. First, the composition of EVs holds important clues about the type and stage of cancer. Second, EVs can potentially be engi-neered for targeted intervention, including stimulation of local autoimmune responses or for 'trapping' of dissemi-nated cancer cells. Finally, during cancer treatment EVs may switch their composi-tion, which can be used for 'real-time' monitoring of therapeutic efficiency. These undertakings are facilitated by the fact that EVs are easily accessible from body fluids. However, many questions remain unan-swered, including a better understanding of the biology of EV biogenesis and EV-specific uptake by recipient cells. In addi-tion, spatial and temporal regulation underlying tumor development may also affect EV composition, a fact often ignored in tissue-culture settings or mouse EVinjection experiments.
In conclusion, the studies briefly described in this review make a sounding case for the involvement of EVs in many stages of cancer development and progression. Hence, the quest to intercept and exploit EV-mediated cellular communication has just begun.
